- Home
- NMCO vs ESPR Comparison
NMCO vs ESPR Comparison
Compare NMCO & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMCO
- ESPR
- Stock Information
- Founded
- NMCO 2019
- ESPR 2008
- Country
- NMCO United States
- ESPR United States
- Employees
- NMCO N/A
- ESPR N/A
- Industry
- NMCO Finance/Investors Services
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- NMCO Finance
- ESPR Health Care
- Exchange
- NMCO Nasdaq
- ESPR Nasdaq
- Market Cap
- NMCO 599.0M
- ESPR 660.1M
- IPO Year
- NMCO N/A
- ESPR 2013
- Fundamental
- Price
- NMCO $10.93
- ESPR $2.94
- Analyst Decision
- NMCO
- ESPR Buy
- Analyst Count
- NMCO 0
- ESPR 6
- Target Price
- NMCO N/A
- ESPR $6.50
- AVG Volume (30 Days)
- NMCO 207.6K
- ESPR 5.5M
- Earning Date
- NMCO 01-01-0001
- ESPR 11-06-2025
- Dividend Yield
- NMCO 5.43%
- ESPR N/A
- EPS Growth
- NMCO N/A
- ESPR N/A
- EPS
- NMCO N/A
- ESPR N/A
- Revenue
- NMCO N/A
- ESPR $268,125,000.00
- Revenue This Year
- NMCO N/A
- ESPR $18.83
- Revenue Next Year
- NMCO N/A
- ESPR N/A
- P/E Ratio
- NMCO N/A
- ESPR N/A
- Revenue Growth
- NMCO N/A
- ESPR N/A
- 52 Week Low
- NMCO $8.52
- ESPR $0.69
- 52 Week High
- NMCO $11.64
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- NMCO 58.49
- ESPR 57.22
- Support Level
- NMCO $10.67
- ESPR $2.80
- Resistance Level
- NMCO $10.82
- ESPR $3.01
- Average True Range (ATR)
- NMCO 0.12
- ESPR 0.17
- MACD
- NMCO 0.01
- ESPR -0.00
- Stochastic Oscillator
- NMCO 86.53
- ESPR 67.31
About NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.